Search
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalBy inhibiting viral protease NS3/4A, voxilaprevir therefore prevents viral replication and function. … Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label].
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigational[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. … Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.
Aminocaproic acid
go.drugbank.com/drugs/DB00513ApprovedInvestigationalAn antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Iopamidol
go.drugbank.com/drugs/DB08947ApprovedInvestigationalIopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.
Hyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigationalHyoscyamine is a tropane alkaloid and the levo-isomer of atropine. It is commonly extracted from plants in the Solanaceae or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyami...
Mixtures: UR N-C Urinary AntisepticSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalby Alkermes Inc. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. In early trials, ISIS 113715 induced statistically significant improvements in multiple measure...
Vibostolimab
go.drugbank.com/drugs/DB16420InvestigationalSubstudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK
Fostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has also been granted orphan drug status by the FDA [L2644].
Glutethimide
go.drugbank.com/drugs/DB01437ApprovedIllicitIts use has been largely superseded by other drugs.